Literature DB >> 24154984

Valproyl-CoA inhibits the activity of ATP- and GTP-dependent succinate:CoA ligases.

Paula B M Luís1, Jos Ruiter, Lodewijk IJlst, Isabel Tavares de Almeida, Marinus Duran, Ronald J A Wanders, Margarida F B Silva.   

Abstract

BACKGROUND: Valproic acid (VPA) is an effective antiepileptic drug that may induce progressive microvesicular steatosis. The impairment of mitochondrial function may be an important metabolic effect of VPA treatment with potential adverse consequences.
OBJECTIVE: To investigate the influence of VPA on the activity of GTP- and ATP-specific succinate:CoA ligases (G-SUCL and A-SUCL).
METHODS: The GTP- and ATP-specific SUCL activities were measured in human fibroblasts in the reverse direction, i.e. the formation of succinyl-CoA. These were assessed at different concentrations of succinate in the presence of VPA, valproyl-CoA and zinc chloride, an established inhibitor of the enzymes. Activities were measured using an optimized HPLC procedure.
RESULTS: Valproyl-CoA (1 mM) inhibited the activity of A-SUCL and G-SUCL by 45-55% and 25-50%, respectively. VPA (1 mM) had no influence on the activity of the two enzymes. DISCUSSION: Valproyl-CoA appears to affect the activity of SUCL, especially with the ATP-specific enzyme. Considering the key role of SUCL in the Krebs cycle, interference with its activity might impair the cellular energy status. Moreover, A-SUCL is bound to the nucleoside diphosphate kinase (NDPK), which is responsible for the mitochondrial (deoxy)nucleotide synthesis. An inhibition of A-SUCL might influence the activity of NDPK inducing an imbalance of nucleotides in the mitochondria and eventually mitochondrial DNA depletion. This may account for the potential liver failure associated with valproate therapy, reported in patients with deficiencies within the mitochondrial DNA replicase system such as polymerase gamma 1.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24154984     DOI: 10.1007/s10545-013-9657-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  41 in total

1.  Expression of two succinyl-CoA synthetases with different nucleotide specificities in mammalian tissues.

Authors:  David O Lambeth; Kristin N Tews; Steven Adkins; Dean Frohlich; Barry I Milavetz
Journal:  J Biol Chem       Date:  2004-07-02       Impact factor: 5.157

Review 2.  Deoxyribonucleotides and disorders of mitochondrial DNA integrity.

Authors:  Ann Saada
Journal:  DNA Cell Biol       Date:  2004-12       Impact factor: 3.311

3.  Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion.

Authors:  Orly Elpeleg; Chaya Miller; Eli Hershkovitz; Maria Bitner-Glindzicz; Gili Bondi-Rubinstein; Shamima Rahman; Alistair Pagnamenta; Sharon Eshhar; Ann Saada
Journal:  Am J Hum Genet       Date:  2005-04-22       Impact factor: 11.025

Review 4.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

5.  Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion.

Authors:  Anna H Hakonen; Pirjo Isohanni; Anders Paetau; Riitta Herva; Anu Suomalainen; Tuula Lönnqvist
Journal:  Brain       Date:  2007-10-05       Impact factor: 13.501

6.  Characterization of nucleoside-diphosphate kinase from Pseudomonas aeruginosa: complex formation with succinyl-CoA synthetase.

Authors:  A Kavanaugh-Black; D M Connolly; S A Chugani; A M Chakrabarty
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

7.  Propionate inhibition of succinate:CoA ligase (GDP) and the citric acid cycle in mitochondria.

Authors:  D A Stumpf; J McAfee; J K Parks; L Eguren
Journal:  Pediatr Res       Date:  1980-10       Impact factor: 3.756

Review 8.  Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.

Authors:  M F B Silva; C C P Aires; P B M Luis; J P N Ruiter; L IJlst; M Duran; R J A Wanders; I Tavares de Almeida
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

9.  A novel missense mutation in SUCLG1 associated with mitochondrial DNA depletion, encephalomyopathic form, with methylmalonic aciduria.

Authors:  Elsebet Ostergaard; Marianne Schwartz; Mustafa Batbayli; Ernst Christensen; Ola Hjalmarson; Gittan Kollberg; Elisabeth Holme
Journal:  Eur J Pediatr       Date:  2009-06-14       Impact factor: 3.183

10.  Prospective study of POLG mutations presenting in children with intractable epilepsy: prevalence and clinical features.

Authors:  Johanna Uusimaa; Vasantha Gowda; Anthony McShane; Conrad Smith; Julie Evans; Annie Shrier; Manisha Narasimhan; Anthony O'Rourke; Yusuf Rajabally; Tammy Hedderly; Frances Cowan; Carl Fratter; Joanna Poulton
Journal:  Epilepsia       Date:  2013-02-28       Impact factor: 5.864

View more
  3 in total

Review 1.  Drug-Induced Mitochondrial Toxicity.

Authors:  Iain P Hargreaves; Mesfer Al Shahrani; Luke Wainwright; Simon J R Heales
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

2.  Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase.

Authors:  Alexei P Kudin; Hafiz Mawasi; Arik Eisenkraft; Christian E Elger; Meir Bialer; Wolfram S Kunz
Journal:  Int J Mol Sci       Date:  2017-09-06       Impact factor: 5.923

3.  Valproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts.

Authors:  Kamil S Sitarz; Hannah R Elliott; Betül S Karaman; Caroline Relton; Patrick F Chinnery; Rita Horvath
Journal:  Mol Genet Metab       Date:  2014-03-28       Impact factor: 4.797

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.